FDA
-
-
-
-
-
-
-
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
-
-
-
-
-
-
-
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Pulmatrix (PULM) Submits IND Application to FDA to Initiate a Phase 2 Trial of PUR3100
-
-
-
-
-
-
-
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
-
-
-
-
-
-
-
Pulmatrix Reports 2020 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Pulmatrix (PULM) Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
-
-
-
-
-
-
-
Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

